Last reviewed · How we verify
Xamiol® Gel
Xamiol® Gel is a Combination topical agent (vitamin D analog + corticosteroid) Small molecule drug developed by LEO Pharma. It is currently FDA-approved for Plaque psoriasis (topical treatment).
Xamiol® Gel combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.
Xamiol Gel is a topical medication used to treat Scalp Psoriasis and Psoriasis Vulgaris, as indicated by ClinicalTrials.gov. The exact mechanism of action of Xamiol Gel is unknown, according to ChEMBL.
At a glance
| Generic name | Xamiol® Gel |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Combination topical agent (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist, promoting differentiation and reducing proliferation of keratinocytes, while betamethasone dipropionate provides anti-inflammatory effects through glucocorticoid receptor activation. Together, these complementary mechanisms address both the hyperproliferation and inflammatory components of psoriatic plaques.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Skin irritation or burning at application site
- Pruritus
- Erythema
- Local skin atrophy (with prolonged use)
Key clinical trials
- Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis (PHASE3)
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population (PHASE4)
- Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)
- Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris (PHASE2)
- Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study
- Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xamiol® Gel CI brief — competitive landscape report
- Xamiol® Gel updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about Xamiol® Gel
What is Xamiol® Gel?
How does Xamiol® Gel work?
What is Xamiol® Gel used for?
Who makes Xamiol® Gel?
What drug class is Xamiol® Gel in?
What development phase is Xamiol® Gel in?
What are the side effects of Xamiol® Gel?
What does Xamiol® Gel target?
Related
- Drug class: All Combination topical agent (vitamin D analog + corticosteroid) drugs
- Target: All drugs targeting Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
- Manufacturer: LEO Pharma — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Plaque psoriasis (topical treatment)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing